Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review
Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Albireo Pharma Inc (Albireo), formerly Biodel Inc, focuses on the development and commercialization of novel bile acid modulators for treatment of orphan pediatric liver diseases, gastrointestinal (GI) disorders and other diseases. Its pipeline products include odevixibat (A4250) intended for treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia, alagille syndrome and other cholestaticc; A3384 for bile acid malabsorption; and elobixibat for nonalcoholic steatohepatitis (NASH). Elobixibat is approved in Japan for the treatment of chronic constipation. The company is investigating bile acid modulator for nonalcoholic steatohepatitis (NASH) and other preclinical trials for the treatment of adult liver diseases. It operates in the US, the UK, and Sweden. Albireo is headquartered in Boston, Massachusetts, the US.
Albireo Pharma Inc Key Recent Developments
Sep 08,2021: Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 05,2021: Albireo Reports Q2 Financial Results and Business Update
Jun 30,2021: Albireo to Report Second Quarter 2021 Financial Results on August 5
Jun 24,2021: Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day
May 06,2021: Albireo Reports Q1 Financial Results and Business Update
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Albireo Pharma Inc (Albireo), formerly Biodel Inc, focuses on the development and commercialization of novel bile acid modulators for treatment of orphan pediatric liver diseases, gastrointestinal (GI) disorders and other diseases. Its pipeline products include odevixibat (A4250) intended for treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia, alagille syndrome and other cholestaticc; A3384 for bile acid malabsorption; and elobixibat for nonalcoholic steatohepatitis (NASH). Elobixibat is approved in Japan for the treatment of chronic constipation. The company is investigating bile acid modulator for nonalcoholic steatohepatitis (NASH) and other preclinical trials for the treatment of adult liver diseases. It operates in the US, the UK, and Sweden. Albireo is headquartered in Boston, Massachusetts, the US.
Albireo Pharma Inc Key Recent Developments
Sep 08,2021: Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aug 05,2021: Albireo Reports Q2 Financial Results and Business Update
Jun 30,2021: Albireo to Report Second Quarter 2021 Financial Results on August 5
Jun 24,2021: Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day
May 06,2021: Albireo Reports Q1 Financial Results and Business Update
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Albireo Pharma Inc - Key Facts
Albireo Pharma Inc - Key Employees
Albireo Pharma Inc - Key Employee Biographies
Albireo Pharma Inc - Major Products and Services
Albireo Pharma Inc - History
Albireo Pharma Inc - Company Statement
Albireo Pharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Albireo Pharma Inc - Business Description
R&D Overview
Albireo Pharma Inc - Corporate Strategy
Albireo Pharma Inc - SWOT Analysis
SWOT Analysis - Overview
Albireo Pharma Inc - Strengths
Albireo Pharma Inc - Weaknesses
Albireo Pharma Inc - Opportunities
Albireo Pharma Inc - Threats
Albireo Pharma Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Albireo Pharma Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Aug 05, 2021: Albireo Reports Q2 Financial Results and Business Update
Jun 30, 2021: Albireo to Report Second Quarter 2021 Financial Results on August
Jun 24, 2021: Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day
May 06, 2021: Albireo Reports Q1 Financial Results and Business Update
Apr 13, 2021: Albireo Expands Leadership with Joan Connolly as Chief Technology Officer
Apr 06, 2021: Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference
Feb 25, 2021: Albireo reports Q4 and year-end 2020 financial results and business update
Feb 23, 2021: Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
Feb 18, 2021: Albireo to Report Q4 and Year-End 2020 Financial Results on February
Jan 05, 2021: Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Albireo Pharma Inc - Key Facts
Albireo Pharma Inc - Key Employees
Albireo Pharma Inc - Key Employee Biographies
Albireo Pharma Inc - Major Products and Services
Albireo Pharma Inc - History
Albireo Pharma Inc - Company Statement
Albireo Pharma Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Albireo Pharma Inc - Business Description
R&D Overview
Albireo Pharma Inc - Corporate Strategy
Albireo Pharma Inc - SWOT Analysis
SWOT Analysis - Overview
Albireo Pharma Inc - Strengths
Albireo Pharma Inc - Weaknesses
Albireo Pharma Inc - Opportunities
Albireo Pharma Inc - Threats
Albireo Pharma Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Albireo Pharma Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Aug 05, 2021: Albireo Reports Q2 Financial Results and Business Update
Jun 30, 2021: Albireo to Report Second Quarter 2021 Financial Results on August
Jun 24, 2021: Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day
May 06, 2021: Albireo Reports Q1 Financial Results and Business Update
Apr 13, 2021: Albireo Expands Leadership with Joan Connolly as Chief Technology Officer
Apr 06, 2021: Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference
Feb 25, 2021: Albireo reports Q4 and year-end 2020 financial results and business update
Feb 23, 2021: Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
Feb 18, 2021: Albireo to Report Q4 and Year-End 2020 Financial Results on February
Jan 05, 2021: Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Albireo Pharma Inc, Key Facts
Albireo Pharma Inc, Key Employees
Albireo Pharma Inc, Key Employee Biographies
Albireo Pharma Inc, Major Products and Services
Albireo Pharma Inc, History
Albireo Pharma Inc, Subsidiaries
Albireo Pharma Inc, Key Competitors
Albireo Pharma Inc, Ratios based on current share price
Albireo Pharma Inc, Annual Ratios
Albireo Pharma Inc, Annual Ratios (Cont...1)
Albireo Pharma Inc, Interim Ratios
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Albireo Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Albireo Pharma Inc, Key Facts
Albireo Pharma Inc, Key Employees
Albireo Pharma Inc, Key Employee Biographies
Albireo Pharma Inc, Major Products and Services
Albireo Pharma Inc, History
Albireo Pharma Inc, Subsidiaries
Albireo Pharma Inc, Key Competitors
Albireo Pharma Inc, Ratios based on current share price
Albireo Pharma Inc, Annual Ratios
Albireo Pharma Inc, Annual Ratios (Cont...1)
Albireo Pharma Inc, Interim Ratios
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Albireo Pharma Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Albireo Pharma Inc, Performance Chart (2016 - 2020)
Albireo Pharma Inc, Ratio Charts
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Albireo Pharma Inc, Performance Chart (2016 - 2020)
Albireo Pharma Inc, Ratio Charts
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021